{"url":"https://newsforagent.com/news/2026-10-24/astrazeneca-durvalumab-tarlatamab-lung-cancer-survival","markdown_url":"https://newsforagent.com/news/2026-10-24/astrazeneca-durvalumab-tarlatamab-lung-cancer-survival.md","title":"AstraZeneca Combo Cuts Death Risk 58% in Lung Cancer","headline":"AstraZeneca Says Durvalumab Plus Amgen's Tarlatamab Cut Death Risk 58% in ES-SCLC Trial","description":"AstraZeneca's Imfinzi plus Amgen's tarlatamab cut death risk 58% in extensive-stage small cell lung cancer, with median survival of 21.1 months.","section":"Research & Clinical Trials","published_at":"2026-10-24T14:56:58+00:00","modified_at":"2026-10-24T14:56:58+00:00","author":"News Desk","key_takeaways":["AstraZeneca said durvalumab plus tarlatamab cut the risk of death by 58% versus durvalumab alone in first-line maintenance ES-SCLC.","Median overall survival was 21.1 months for the combination versus 12.7 months for durvalumab alone.","Progression-free survival was 7.4 months versus 1.9 months, and the objective response rate was 26.4% versus 4.1%."],"companies":[{"name":"AstraZeneca","is_primary":true,"profile_url":"https://akta.pro/company-profiles/000026p/astrazeneca","website":"https://www.astrazeneca.com"},{"name":"Amgen Inc.","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0000459/amgen-inc","website":"https://www.amgen.com.sg"}],"source":{"publisher":"TradingView","title":"AstraZeneca (AZN) Says Durvalumab+Tarlatamab Cut Death Risk 58% in ES-SCLC Phase III","url":"https://www.tradingview.com/news/tradingview:a17d9bd435023:0-astrazeneca-azn-says-durvalumab-tarlatamab-cut-death-risk-58-in-es-sclc-phase-iii/"},"other_sources":[{"publisher":"Mirage News","url":"https://www.miragenews.com/immunotherapy-combo-extends-survival-in-1766009/"},{"publisher":"Yahoo","url":"https://www.yahoo.com/news/science/articles/amgen-drug-combined-immunotherapy-extends-143307294.html"}],"tags":["Research & Clinical Trials","AstraZeneca","Amgen Inc."],"body_markdown":"[AstraZeneca](https://akta.pro/company-profiles/000026p/astrazeneca) said its IMFINZI (durvalumab) combined with [Amgen](https://akta.pro/company-profiles/0000459/amgen-inc)'s tarlatamab-dlle cut the risk of death by 58% versus IMFINZI alone in first-line maintenance extensive-stage small cell lung cancer, with median overall survival of 21.1 months versus 12.7 months. The results were published by [TradingView](https://www.tradingview.com/news/tradingview:a17d9bd435023:0-astrazeneca-azn-says-durvalumab-tarlatamab-cut-death-risk-58-in-es-sclc-phase-iii/).\n\n## AstraZeneca's Phase III Survival Results\n\nThe trial reported an overall survival hazard ratio of 0.42 with a p-value below 0.001, and a progression-free survival hazard ratio of 0.34, a 66% reduction in the risk of progression or death, also with a p-value below 0.001. Median progression-free survival was 7.4 months versus 1.9 months, and the objective response rate was 26.4% versus 4.1%. Safety was consistent with the known profiles of the two drugs, and no treatment-related deaths were reported.\n\n[Yahoo](https://www.yahoo.com/news/science/articles/amgen-drug-combined-immunotherapy-extends-143307294.html) reported that Amgen's Imdelltra combined with AstraZeneca's Imfinzi reduced death risk by 58% in extensive-stage small cell lung cancer, with median survival of 21.1 months versus 12.7 months on Imfinzi alone. Yahoo also reported that the combination was approved for advanced small cell lung cancer, and that Amgen estimates annual sales exceeding $2.5 billion by 2030.\n\nAstraZeneca is a global pharmaceutical company that develops and markets oncology, cardiometabolic, rare disease, and respiratory prescription medicines, including ADC therapies (Enhertu, Datroway) and oral GLP-1 (elecoglipron), serving patients, healthcare providers, and payers across 13+ countries, according to akta.pro [company records](https://akta.pro/company-data).\n\n## AstraZeneca's Oncology Scale\n\nAstraZeneca reported full-year revenue of $60.4 billion with a 17.2% net margin, and Q1 2026 revenue of $12.68 billion, up 19% with 26% oncology sales growth, according to company records. Management guidance targets annual sales of $80 billion by 2030, with 20 planned drug launches. Bernstein forecast $89.06 billion by 2030, above the company's guidance and the Bloomberg consensus of $82 billion.\n\n## Earlier AstraZeneca Approvals and Partnerships\n\nOn October 21, 2026, Reuters reported that AstraZeneca said the FDA granted accelerated approval for its drug Ultomiris for adults with immunoglobulin A nephropathy, a rare kidney disease. On the same date, In Vivo reported that AstraZeneca's Breztri Aerosphere received US approval for COPD and asthma via a supplemental new drug application. On October 20, 2026, Jiemian reported that Oracle and AstraZeneca announced a non-binding agreement to explore AI and real-world data for identifying clinical trial patients and accelerating medical evidence.\n\n## What Comes Next for the Combination\n\nAstraZeneca is expected to report Q3 2026 earnings on Friday, October 30th, according to MarketBeat. [Mirage News](https://www.miragenews.com/immunotherapy-combo-extends-survival-in-1766009/) reported that researchers will continue a Phase 3 trial of durvalumab plus olaparib after chemotherapy in advanced endometrial cancer for a final overall survival analysis.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}